Publications by authors named "Mercedes Acevedo"
Article Synopsis
- The activation of the alternative pathway (AP) of the complement system plays a significant role in the development of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but the exact mechanisms are not fully understood.
- Researchers analyzed gene variants and plasma levels of different complement components in a Spanish cohort of 102 AAV patients to explore the impact of the AP on the disease.
- The study found that specific genetic variants influence disease susceptibility and kidney damage severity, while high levels of AP activation and certain plasma component ratios correlate with worse outcomes, highlighting FHR-1 as a potential therapeutic target.
Background: Recently, renal risk score on the basis of three clinicopathologic features to predict end-stage renal disease (ESRD) in antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis has been proposed. The aim of this multi-centre study was to validate this renal risk score in a large cohort of southern European patients.
Methods: Data were retrospectively collected from the time of diagnosis by systematic review of medical records from 147 patients with renal vasculitis recruited from three Spanish centres.
Background: Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis is a chronic relapsing and remitting autoimmune disease. Urinary soluble CD163 (usCD163) has been proposed as a biomarker of active renal vasculitis. We aimed to assess the potential usefulness of usCD163 for diagnosing renal relapse in patients with ANCA-associated glomerulonephritis.
View Article and Find Full Text PDFRenal failure secondary to ANCA-associated vasculitis represents a clinical and therapeutic challenge. In this study, we aimed to assess the treatment response rates and long-term outcomes of vasculitis patients presenting with renal failure. This retrospective study included 151 patients with renal vasculitis from three hospitals who underwent a renal biopsy between 1997 and 2014.
View Article and Find Full Text PDFArticle Synopsis
- This study investigated how serum C3 levels affect outcomes in patients with renal vasculitis, highlighting the importance of complement activation in this disease.* -
- Researchers analyzed data from 111 patients who underwent renal biopsies, categorizing their serum C3 levels into three groups and measuring outcomes like dialysis needs and survival rates.* -
- Results showed that lower serum C3 levels were linked to worse outcomes, including a higher risk of end-stage renal disease and lower overall survival, suggesting that these levels could be used as a prognostic marker.*
Pauci-immune necrotizing crescentic glomerulonephritis is the histologic substrate of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Several studies in animal models have demonstrated the crucial role of complement activation in the pathogenesis of ANCA-associated vasculitis, but only small series have analyzed the prognostic implications of complement glomerular deposits. This study aimed to assess the clinical and prognostic implications of C3d- and C4d-positive glomerular staining in renal vasculitis.
View Article and Find Full Text PDFThe histopathologic classification of antineutrophil cytoplasmic antibody-associated vasculitis has been demonstrated to have prognostic value in small cohorts of patients with pauci-immune extracapillary glomerulonephritis. We aimed to validate this histologic subgrouping system in a large cohort of patients with renal vasculitis from 3 Spanish centers. The additional value of several histologic parameters for predicting renal outcome was investigated.
View Article and Find Full Text PDFAim: Pauci-immune extracapillary glomerulonephritis (PEGN) is one of the most common causes of rapidly progressive glomerulonephritis and is usually associated with circulating anti-neutrophil cytoplasmic antibodies (ANCAs). However, a significant number of individuals with PEGN test negative for ANCA and this study aimed to analyze the characteristics of this subgroup of patients.
Methods: Patients from two centres who were diagnosed with PEGN between 1997 and 2014 were studied retrospectively.